12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALKS 37: Development discontinued

Alkermes discontinued development of ALKS 37 after top-line data from a double-blind, placebo-controlled, U.S. Phase IIb trial in about 150 patients with OIC showed that ALKS 37's product profile did not satisfy undisclosed pre-specified criteria for advancing into Phase III trials. The company did say that patients receiving ALKS...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >